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axiong@xmu.edu.cAbstract A predictive pharmacophore model has been generated from a series of diverse fatty acid
amide hydrolase (FAAH) inhibitors and the optimal pharmacophore model applied in virtual
screening. The pharmacophore model was based on a training set of 21 compounds carefully
selected from the published literatures. The optimal model Hypo-1 included four features (two
hydrogen-bond acceptor units, one aromatic hydrophobic unit and one aromatic ring unit) and two
excluded volumes. Cross-validation of the model conﬁrmed that Hypo-1 was not generated by
chance correlation. A large test set of 55 compounds showed that Hypo-1 performed well in
classifying highly active and less active FAAH inhibitors. Superimposition analysis of the FAAH
X-ray crystal structure and the pharmacophore Hypo-1 further validated the adequacy of the
model. Virtual screening generated a total of 976 hits from the Zinc Natural Products database, a
hit rate of 1.04% and enrichment of 83.89. The acceptable hit rate further supports the use of
Hypo-1 as a 3D query tool for virtual screening.
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Dong-sheng Zhao et al.281. Introduction
Fatty acid amide hydrolase (FAAH) is an integral membrane
protein primarily responsible for the catabolism of the fatty
acid amide (FAA) family of endogenous signaling lipids.
Substrates of FAA include the endogenous cannabinoids
(endocannabinoid), N-arachidonoylethanolamine (ananda-
mide) and 2-arachidonoylglycerol (2-AG)1. The endocannabi-
noid system is composed of two G-protein-coupled receptors,
CB1 and CB22, which are activated by signaling lipids to
modulate a range of mammalian behaviors including pain,
inﬂammation, appetite, motility, sleep, thermoregulation, cog-
nition and emotional state3.
FAAH inhibition leads to elevated endogenous levels of
FAAs and a range of behavioral effects. FAAH inhibition
offers an attractive way to activate the endocannabinoid
system without many side effects associated with the use of
direct cannabinoid receptor agonists4. The past 10 years have
seen an explosion in the number and quality of FAAH
inhibitors available for pharmacological evaluation, includingURB880                       URB597                 
URB602                       JP83                    
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Figure 1 Molecular structures ofthe compounds that have shown promising in vivo activity,
selectivity and therapeutic effects5. Kimball et al.6 introduced
a large number of potential inhibitors based on a-ketohetero-
cycles (e.g. OL135, Fig. 1) that reversibly form hemiketals with
the active site serine of FAAH; Mor et al.7 introduced another
class of inhibitors derived from N-alkylcarbamates (e.g.
URB597, Fig. 1) that irreversibly acylate the active site serine
of FAAH. Other recently reported structures with inhibitory
activity against FAAH include piperidine and piperazine
ureas8, sulfonyl derivatives9, (thio)hydantoins10, boronic acid
derivatives11 and b-lactam derivatives12.
A chemical features based pharmacophore model may serve
as a guide in the screening of potential inhibitors. A pharma-
cophore represents the three-dimensional arrangement of
structural or chemical features of a drug essential for optimal
binding to the receptor13. In this report, we present the
generation and validation of a pharmacophore model of
FAAH inhibitors using the Discovery Studio 2.1/‘‘3D QSAR
Pharmacophore Generation’’ protocol. We also present the
results of virtual screening.      URB524                         URB532 
      Training04                       PF622 
92                             CAY10402       
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the 21 training set compounds.
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2.1. Molecular modeling
Molecular modeling was performed on a Silicon Graphics
work station (IBM Z-PRO 107) using Hyperchem 6.0 software
for molecular structure optimization and Discovery Studio 2.1
software (Accelrys Inc., San Diego, CA) for pharmacophore
models generation and virtual screening.
2.2. Training set and test set compound selection
Based on the published literatures, we collected 21 typical
compounds7,12,14–22 (Fig. 1) as a training set to generate
pharmacophore models of FAAH inhibitors according to a
three-dimensional quantitative structure–activity relationship.
Inhibitory activity as measured by IC50 values was in the range
0.4–5700 nmol/L spanning 5 orders of magnitude. To validate
the pharmacophore models obtained, 55 FAAH inhibi-
tors7,12,14–31 (Fig. 2) were selected to compose the test set.
For estimation purposes, activity was classiﬁed as follows:
IC50o100 nmol/L highly active (represented as þþ); 100r
IC50o1000 nmol/L moderately active (represented as þ) and
IC50Z1000 nmol/L less active (represented as ).
2.3. Conformational analysis
Initially all training and test set structures were generated and
optimized using Hyperchem 6.0 software. All structures were
minimized using the Polak–Ribiere (conjugate-gradient) algo-
rithm with a RMS gradient set at 0.01 kcal/mol. To take into
account the molecular ﬂexibility, the protocol ‘‘Diverse
Conformation Generation’’ in Discovery Studio 2.1 was
applied to both sets of molecules using the Poling algorithm
and selecting the ‘‘best’’ conformer generation option with an
energy threshold of 20 kcal/mol and a maximum conforma-
tion number of 300.
2.4. Generation of pharmacophores
An initial analysis of the training set using the ‘‘Create 3D
Fingerprints’’ protocol revealed that hydrogen-bond acceptor
(HBA), hydrophobic (HY) and aromatic ring (RA) features
effectively mapped the critical structural/chemical features of
all training set molecules. On this basis, we selected HBA, HY
(including hydrophobic aromatic (HY_ar), hydrophobic
aliphatic (HY_al)) and RA features for the ‘‘3D QSAR
Pharmacophore Generation’’ protocol. The minimum and
the maximum number of selected features were set at 0 and
5, respectively, the maximum number of excluded volumes
(EV) at 4, the uncertainty value at 2 (deﬁned by software
Discovery Studio as a ratio of the reported value to the
minimum and maximum values) and the Fischer validation
at 95%.
3. Results and discussion
3.1. Pharmacophore generation
The 3D QSAR pharmacophore generation protocol generated
a set of 10 pharmacophore hypotheses from the 21 training setcompounds. All hypotheses showed high correlations indicat-
ing their stability. Three or four features (HBA, RA, HY and
HY_ar) and several excluded volumes (Table 1) were con-
sidered in all the hypotheses. The total cost of each hypothesis
is close to the ﬁxed cost and very different to the null cost
value, indicating good hypotheses. The conﬁguration value of
these hypotheses is 15.63, which, being less than 17, is within
the allowed range.
The optimal pharmacophore hypothesis, i.e. the one with
the highest correlation, the lowest RMS and the lowest total
cost, was named Hypo-1. It consisted of four features (HBA1,
HBA2, HY_ar and RA) and two excluded volumes (EV1 and
EV2) (Fig. 3). The RMS value of 1.47, correlation coefﬁcient
of 0.926 and cost difference of 112.09 (Table 1) demonstrate
that there is 490% probability of accurately predicting the
activities of compounds in the training set. The reason for the
rather high value of RMS is that the uncertainty value was set
at 3 not at 2.
Table 2 shows the actual and estimated IC50 values of
training set molecules with error values, ﬁt values and
matching degrees with the pharmacophore Hypo-1. On the
basis of the activity scale mentioned above, only one highly
active (þþ) compound was underestimated as moderate
activity (þ), one less active () compound was overestimated
as moderate activity (þ) and no highly active (þþ) compound
was estimated as less active () and vice versa. This indicates
that the pharmacophore Hypo-1 classiﬁes the training set
compounds correctly. Fig. 3 shows the highly active com-
pound OL92 and the less active compound URB602 mapped
on Hypo-1; OL92 mapped well but URB602 missed two
features. Overall, the mapping results suggest that the phar-
macophore Hypo-1 provides a reasonable representation of
the pharmacophore of FAAH inhibitors.
3.2. Cross-validation study
The quality of the best pharmacophore hypothesis was
assessed using the Fischer validation (CatScramble test) in
Discovery Studio 2.1. This technique randomly reassigns the
activity values of the training set compounds and then creates
new spreadsheets to validate the strong correlation between
chemical structure and biological activity of training set
compounds. A total of 19 randomizations are created when
the Fischer validation is set at 95%.
The results of the Fischer validation are shown in Table 3.
The results clearly indicate that in the 19 randomizations, all
correlations are less than 0.76 and all cost values are more
than that of Hypo-1. These cross-validation results verify that
there is a 95% chance that Hypo-1 represents a true correla-
tion in the training set activity data.
3.3. Validation of Hypo-1 in the test set
The test set of 55 reported FAAH inhibitors was analyzed
to check the predictive capability of Hypo-1. The ‘‘Ligand
Pharmacophore Mapping’’ protocol with Maximum Omitted
Features set at 2 and the Fitting Method of Rigid in Discovery
Studio 2.1 was used to estimate the activities of the test set
compounds. The estimated activities and actual activities are
compared in Table 4. Of the 30 highly active (þþ) com-
pounds, none was classiﬁed as less activity () and only one
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Figure 2 Molecular structures of the 55 test set compounds.
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Table 1 Statistical signiﬁcance, predictive power and features of the top-10 pharmacophore hypotheses derived from the training
set of molecule.
Hypothesis Correlationa RMSb Total cost DCostc Featuresd EV
Hypo-1 0.926 1.47 106.63 112.09 HBA HBA RA HY_ar 2
Hypo-2 0.922 1.55 117.08 101.64 HBA HBA HY HY_ar 3
Hypo-3 0.918 1.54 106.84 111.88 HBA HBA RA HY_ar 3
Hypo-4 0.906 1.67 117.34 101.38 HBA HBA HY_ar 2
Hypo-5 0.899 1.74 122.9 95.82 HBA HBA HY HY_ar 2
Hypo-6 0.896 1.73 118.01 100.71 HBA HBA HY RA 4
Hypo-7 0.892 1.77 118.94 99.78 HBA HBA HY HY_ar 3
Hypo-8 0.881 1.84 120.7 98.02 HBA HBA HY HY_ar 4
Hypo-9 0.877 1.87 120.95 99.77 HBA HBA HY 3
Hypo-10 0.865 1.95 124.4 94.32 HBA HBA HY RA 3
Fixed cost¼80.3, null cost¼218.72 and conﬁguration¼15.63.
aCorrelation coefﬁcient based on linear regression derived from the geometric ﬁt index.
bRMS, the deviation of log (estimated activity) from log (measured activity) normalized to log (uncertainty).
cDCost¼null costtotal cost.
dHBA, hydrogen-bond accepter; HY, hydrophobic; HY_ar, hydrophobic_aromatic; EV, excluded volume.
Figure 3 Mapping of top scoring pharmacophore Hypo-1 on (a) highly active training set compound OL92; (b) less active training set
compound URB602; (c) highly active test set compound test 55 and (d) less active test set compound test 52. Cyan sphere, HBA; green
sphere, HY_ar; yellow/brown sphere, RA; black sphere, EV.
Pharmacophore modeling and virtual screening for new FAAH inhibitors 31was underestimated as moderately active (þ); of the 16
moderately active (þ) compounds, all were predicted cor-
rectly; of the other 9 less active () compounds, none was
overestimated as highly active (þþ) but 7 were classiﬁed as
moderately active (þ) with most of their error values close to
1. On this basis, it can be concluded that Hypo-1 is clearly able
to correctly classify the compounds outside the training set.
Mapping of one highly active and one less active compound in
the test set on Hypo-1 is shown in Fig. 3(c) and (d).3.4. X-ray crystallographic analysis
Mileni et al.4 presented the X-ray crystal structure of the complex
of OL135 and FAAH (PDB ID: 2WJ2) (Fig. 4). Superposition ofHypo-1 onto FAAH reveals a good agreement of the critical
interacting chemical features. As shown in Fig. 4, OL135 in the
crystal structure and in the training set adopts the similar
conformations, the pyridine group, oxazole group and benzene
ring separately mapping onto the HY_ar, HBA1 and RA groups
correctly. In the X-ray crystal structure, the hydrophobic tail and
the phenyl group of OL135 are compressed by the hydrophobic
and aromatic Phe381, Phe432, Met436 and Met495 residues to
form a complementary cavity with a corresponding RA feature;
FAAH has an unusual Ser241–Ser217–Lys142 catalytic triad, the
carbonyl group of OL135 undergoing nucleophilic attack by the
Ser241 residue. Corresponding to Hypo-1, there is an HBA
feature indicating that potential hits must have a hydrogen-bond
accepter group at this position. The HY_ar feature of Hypo-1 is
also compressed by the hydrophobic Phe381, Leu278 and
Table 2 Actual IC50 values and their estimated IC50 of 21 training set molecules calculated on the basis of the pharmacophore
Hypo-1.
No. Name Fita Mappingb Est.c (nmol/L) Est. scale Act. scale Act.d (nmol/L) Errore
HBA1 HBA2 HY_ar RA
1 Training05 8.94 16 24 28 1
 
0.34 þþ þþ 0.4 1.2
2 OL92 8.05  17 20 1  2.6 þþ þþ 0.44 þ5.9
3 URB880 8.75 20 6 21 12
 
0.52 þþ þþ 0.63 1.2
4 BMS1 7.88 15 26 31   3.9 þþ þþ 2 þ1.9
5 Training06 7.64  19 22 1  6.6 þþ þþ 2 þ3.3
6 URB597 7.46 25 11  17  10 þþ þþ 4.6 þ2.2
7 Training01 7.53 23 3 1   8.5 þþ þþ 5 þ1.7
8 CAY10402 7.88  15 19 1  3.8 þþ þþ 9 2.4
9 Training04 7.54 27  2 19  8.3 þþ þþ 12 1.4
10 JP83 7.56 15  29 1  7.9 þþ þþ 14 1.8
11 OL135 7.24  17 23 1  17 þþ þþ 15 þ1.1
12 PF622 6.9  26 23 4  36 þþ þþ 33 þ1.1
13 Training08 7.08  12 4 14  24 þþ þþ 43 1.8
14 ARC70484xx 6.92 32 18 16   35 þþ þþ 59 1.7
15 URB524 5.62  4 8   600 þ þþ 63 þ9.5
16 Training07 7.14 31 15 1   21 þþ þþ 64 3
17 URB532 5.62  15 10   700 þ þ 390 þ1.8
18 Training02 5.61   20 1  710 þ þ 400 þ1.8
19 SPB03742 6.12  10 12 22  220 þ þ 690 3.2
20 Training03 5.65 24 5  17  660 þ  4000 6.1
21 URB602 5.3  11 13   1500   5700 3.9
aFit value calculated by geometry ﬁtting between the hypothesis and the compound; the higher the value, the better the ﬁt.
bMatching degree of pharmacophore element with the speciﬁc conformation of the compound; n means no matching; HBA, hydrogen-
bond accepter; HY, hydrophobic; HY_ar, hydrophobic_aromatic; EV, excluded volume.
cEstimated IC50 value.
dActual IC50 value.
eError factor calculated as the ratio of the measured activity to the estimated activity or the inverse if the estimated activity is greater than
the measured activity. If measured activity is greater than the estimated activity, the error factor is negative and vice versa.
Table 3 Results from cross-validation run using CatScramble technique.
Validation Cost Correlation Validation Cost Correlation
Unscrambled 106.63 0.926 Random10 162.8 0.7
Random1 170.69 0.685 Random11 176.68 0.613
Random2 161.6 0.689 Random12 151.72 0.737
Random3 175.09 0.626 Random13 154.88 0.729
Random4 174.43 0.649 Random14 153.37 0.733
Random5 166.85 0.676 Random15 172.49 0.64
Random6 165.35 0.667 Random16 154.96 0.736
Random7 176.33 0.634 Random17 155.72 0.752
Random8 156.89 0.73 Random18 153.05 0.737
Random9 165.58 0.689 Random19 163.5 0.691
Dong-sheng Zhao et al.32MET191 residues. In conclusion, the superposition studies
provide strong evidence that Hypo-1 is a good representation
of the pharmacophore of FAAH inhibitors.
3.5. Virtual screening
In order to further validate the discriminatory power of
Hypo-1 and to discover new potential FAAH inhibitors, 30
active FAAH inhibitors and 93,527 molecules from the ZincNatural Products database (2008.05)32 (to serve as decoy) were
screened. FAAH inhibitor enrichment of the database com-
pounds was expressed as enrichment factor (EF) calculated
using the following equation33:
EF¼ TP=n
A=N
where TP is the number of FAAH inhibitors matched by
Hypo-1, n is the number of FAAH inhibitors and decoy
Table 4 Actual IC50 values and their estimated IC50 of 55 test set molecules calculated on the basis of the pharmacophore
Hypo-1.
Name Fita Est.b
(nmol/L)
Est.
scale
Act.
scale
Act.c
(nmol/L)
Errord Name Fita Est.b
(nmol/L)
Est.
scale
Act.
scale
Act.c
(nmol/L)
Errord
Test01 5.62 694.6 þ þ 360 þ1.93 Test29 6.82 43.99 þþ þþ 64 1.45
Test02 6.86 39.85 þþ þþ 11 þ3.62 Test30 7.09 23.53 þþ þþ 4 þ5.88
Test03 5.62 688.81 þ  1857 2.7 Test31 7 28.66 þþ þþ 26.7 þ1.07
Test04 7.44 10.47 þþ þþ 49.6 4.74 Test32 6.9 36.75 þþ þþ 10.3 þ3.57
Test05 7.36 12.54 þþ þþ 26.5 2.11 Test33 7.37 12.3 þþ þþ 13 1.06
Test06 7.25 16.4 þþ þþ 9.1 þ1.8 Test34 6.69 59.21 þþ þþ 23 þ2.57
Test07 5.62 694.05   1700 2.45 Test35 6.1 232.81 þ  1167 5.01
Test08 8.75 0.52 þþ þþ 0.63 1.21 Test36 7.19 18.64 þþ þþ 70 3.75
Test09 5.55 810.35 þ þ 252 þ3.22 Test37 6.6 72.99 þþ þþ 64 þ1.14
Test10 5.59 742.71 þ þ 176 þ4.22 Test38 7.56 7.94 þþ þþ 12 1.51
Test11 5.61 704.32 þ  1029 1.46 Test39 7.62 6.95 þþ þþ 34 4.9
Test12 5.62 688.04 þ  2737 3.98 Test40 7.15 20.71 þþ þþ 50 2.41
Test13 5.61 705.46 þ  3776 5.35 Test41 5.62 687.77 þ þ 109 þ6.31
Test14 5.62 693.24 þ þ 766 1.1 Test42 7.7 5.83 þþ þþ 7 1.2
Test15 5.62 688.73 þ þ 696 1.01 Test43 6.64 65.5 þþ þþ 90 1.37
Test16 5.62 688 þ þ 113 þ6.09 Test44 6.58 75.85 þþ þþ 30 þ2.53
Test17 6.29 147.92 þ þþ 33 þ4.48 Test45 7.69 5.9 þþ þþ 20 3.39
Test18 5.61 706.06 þ þ 160 þ4.41 Test46 5.61 707.2 þ þ 400 þ1.77
Test19 5.61 698.38 þ þ 690 þ1.01 Test47 7.17 19.62 þþ þþ 3 þ6.54
Test20 5.62 687.73 þ þ 139 þ4.95 Test48 5.87 394.02 þ þ 315 þ1.25
Test21 7.17 19.73 þþ þþ 5.3 þ3.72 Test49 5.62 688.3 þ  2100 3.05
Test22 6.6 73.57 þþ þþ 13 þ5.66 Test50 5.62 687.68 þ þ 590 þ1.16
Test23 6.82 43.4 þþ þþ 25 þ1.74 Test51 5.46 991.4 þ  1200 1.21
Test24 5.61 710.87 þ þ 174 þ4.09 Test52 5.38 1193.39   5700 4.78
Test25 5.61 706.13 þ þ 324 þ2.17 Test53 7.66 6.27 þþ þþ 2 þ3.13
Test26 5.62 687.7 þ þ 808 1.17 Test54 7.68 6.01 þþ þþ 30 4.99
Test27 7.91 3.55 þþ þþ 10 2.82 Test55 8.81 0.45 þþ þþ 0.4 þ1.12
Test28 7.88 3.82 þþ þþ 13 3.4
aFit value calculated by geometry ﬁtting between the hypothesis and compound; the higher the value, the better the ﬁt.
bEstimated IC50 value.
cActual IC50 value.
dError factor calculated as the ratio of measured activity to estimated activity or the inverse if the estimated activity is greater than the
measured activity. If measured activity is greater than estimated activity, the error factor is negative and vice versa.
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Figure 4 Superposition of the pharmacophore Hypo-1 with the FAAH crystal structure. The molecule in red is OL135 in the crystal
structure and the molecule in blue is OL135 in the training set.
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Figure 5 Mapping of the hit compounds (a) ZINC06623865 and (b) ZINC02260731 from the Zinc Natural Products database onto the
pharmacophore Hypo-1. Cyan sphere, HBA; green sphere, HY_ar; yellow/brown sphere, RA; black sphere, EV.
Dong-sheng Zhao et al.34molecules matched by the model, A is the number of known
FAAH inhibitors in the decoy and N is the number of
compounds in the decoy. As before ﬂexibility was taken into
account by applying the ‘‘Diverse Conformation Generation’’
protocol in Discovery Studio 2.1. This generates diverse
conformers for all the compounds in the database using the
Poling algorithm by ﬁrst selecting the best conformer genera-
tion option with an energy threshold of 20 kcal/mol and a
maximum conformation number of 300 and then using the
‘‘Ligand Pharmacophore Mapping’’ protocol with the same
parameters as in the test set analysis. In this way 27 of 30
FAAH inhibitors (90%) and 976 compounds in the Zinc
Natural Products database ( hit rate of 1.04%) matched
Hypo-1 model with estimated IC50 valueso100 nmol/L.
Taking this into account, an EF of 83.89 was calculated
for Hypo-1, showing it is highly restrictive in picking hits
from a chemistry database. The high performance of this
virtual screening further proves that Hypo-1 is very useful as
a 3D query tool in the screening of other databases.
Two compounds from the Zinc Natural Products database
predicted to be highly active (ZINC06623865 and
ZINC02260731) based on mapping onto Hypo-1 are shown
in Fig. 5.4. Conclusions
This paper reports the use of ligand-based pharmacophore
generation and virtual screening methods to identify the ligand
requirements of FAAH inhibitors. The study presents the 3D
QSAR pharmacophore models for FAAH inhibitors and
establishes that the best pharmacophore Hypo-1 contains four
features (two hydrogen-bond acceptors, one aromatic hydro-
phobic group and one aromatic ring group) and two excluded
volumes. The pharmacophore model provides high predict-
ability for estimating the activities of a variety of compounds.
The virtual screening results provide a total of 976 new hits
from 93,527 molecules, proving the model is highly restrictive
in picking up the novel hits from the chemical databases. To
progress the discovery of novel FAAH inhibitors, some of the
hit compounds are currently synthesized and tested for activity
determined. In addition, the pharmacophore Hypo-1 mapping
approach is shown to be useful in understanding the impor-
tance of various chemical features in FAAH inhibitors, in
further virtual screening and in the design and optimization of
a new generation of FAAH inhibitors.References
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